Abstract
Vaccines are the best defense available against infectious diseases. Vaccine safety is of major focus for regulatory bodies, vaccine manufacturers, public health authorities, health care providers and the public as vaccines are often given to healthy children and adults as well as to pregnant woman. Safety assessment is critical at all stages of vaccine development. Effective, clear and consistent communication of the risks and benefits of vaccines and advocacy during all stages of clinical research (including the preparation, approvals, conduct of clinical trials through the post marketing phase) is critically important. This needs to be done for all major stakeholders (e.g. community members, Study Team, Health Care Providers, Ministry of Health, Regulators, Ethics Committee members, Public Health Authorities and Policy Makers). Improved stakeholder alignment would help to address some of the concerns that may affect the clinical research, licensing of vaccines and their wide-spread use in immunization programs around the world.
Keywords: Adverse events, clinical research, communicating, pharmacovigilance, safety, vaccine introduction.
Current Drug Safety
Title:Communicating Vaccine Safety During the Development and Introduction of Vaccines
Volume: 10 Issue: 1
Author(s): Sonali Kochhar
Affiliation:
Keywords: Adverse events, clinical research, communicating, pharmacovigilance, safety, vaccine introduction.
Abstract: Vaccines are the best defense available against infectious diseases. Vaccine safety is of major focus for regulatory bodies, vaccine manufacturers, public health authorities, health care providers and the public as vaccines are often given to healthy children and adults as well as to pregnant woman. Safety assessment is critical at all stages of vaccine development. Effective, clear and consistent communication of the risks and benefits of vaccines and advocacy during all stages of clinical research (including the preparation, approvals, conduct of clinical trials through the post marketing phase) is critically important. This needs to be done for all major stakeholders (e.g. community members, Study Team, Health Care Providers, Ministry of Health, Regulators, Ethics Committee members, Public Health Authorities and Policy Makers). Improved stakeholder alignment would help to address some of the concerns that may affect the clinical research, licensing of vaccines and their wide-spread use in immunization programs around the world.
Export Options
About this article
Cite this article as:
Kochhar Sonali, Communicating Vaccine Safety During the Development and Introduction of Vaccines, Current Drug Safety 2015; 10 (1) . https://dx.doi.org/10.2174/157488631001150407110435
DOI https://dx.doi.org/10.2174/157488631001150407110435 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Muscarinic Receptor Agonists and Antagonists in the Treatment of Alzheimers Disease
Current Pharmaceutical Design A Comparative Summary on Antioxidant-like Actions of Timolol with Other Antioxidants in Diabetic Cardiomyopathy
Current Drug Delivery Meet Our Editorial Board Member
Current Topics in Medicinal Chemistry Effects of Dietary Polyunsaturated Fatty Acids on Mitochondria
Current Pharmaceutical Design MicroRNA Therapeutics in Neurological Disease
Current Pharmaceutical Design Potential Therapeutic Interest of Adenosine A2A Receptors in Psychiatric Disorders
Current Pharmaceutical Design Organometallic Complexes: New Tools for Chemotherapy
Current Medicinal Chemistry Rationale of Hyperbaric Oxygenation in Cerebral Vascular Insult
Current Vascular Pharmacology Emerging Drugs and Indications for Cardio-Metabolic Disorders in People with Severe Mental Illness
Current Pharmaceutical Design A ‘Cosmopolis’ as the Foundation for Understanding Cultural Differences
Neuroscience and Biomedical Engineering (Discontinued) Scope and Limitations of The Co-Drug Approach to Topical Drug Delivery
Current Pharmaceutical Design Involvement of Cytosolic Phospholipase A2, Calcium Independent Phospholipase A2 and Plasmalogen Selective Phospholipase A2 in Neurodegenerative and Neuropsychiatric Conditions
Current Medicinal Chemistry The Scatter Factor Signaling Pathways as Therapeutic Associated Target in Cancer Treatment
Current Medicinal Chemistry Triphenyl Phosphite-mediated “Green” Synthesis of Novel Carboxycoumarin Amides
Current Green Chemistry An fMRI-EEG Integrative Method with Model Selection Procedures for Reconstruction of Multiple Cortical Activities
Neuroscience and Biomedical Engineering (Discontinued) Niacin Status, NAD Distribution and ADP-Ribose Metabolism
Current Pharmaceutical Design Blood-Brain Barrier Transport of Drugs for the Treatment of Brain Diseases
CNS & Neurological Disorders - Drug Targets Turning Tumor-Promoting Copper into an Anti-Cancer Weapon via High-Throughput Chemistry
Current Medicinal Chemistry Editorial[Hot Topic:Membrane Channels as Therapeutic Targets (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design DREADD in Parvalbumin Interneurons of the Dentate Gyrus Modulates Anxiety, Social Interaction and Memory Extinction
Current Molecular Medicine